Skip to content

Myopic Macular Haemorrhages

Myopic Macular Haemorrhages

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00345228
Enrollment
30
Registered
2006-06-27
Start date
2004-06-30
Completion date
2006-12-31
Last updated
2006-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopic Macular Haemorrhages

Keywords

High myopia, Choroidal neovascularisation, Lacquer crack, Fundus fluorescein angiography, Indocyanine green angiography, Axial length

Brief summary

1. To identify the underlying causes of macular haemorrhages in patients with high myopia 2. In the eyes found to have macular haemorrhages secondary to choroidal neovascularisation, we hope to identify the risk factors for the development of choroidal neovascularisation in high myopia 3. To study the functional outcome of these eyes as assessed by visual acuity 4. To study the morphological outcome of these eyes by clinical assessment (and fundal photography) and fluorescein angiography

Detailed description

Primary Aims * To identify the underlying aetiologies of macular haemorrhages in myopic eyes * To study the functional and morphological outcome of these eyes with macular haemorrhages 6 months later Secondary Aims * To study the subgroup of eyes with myopic choroidal neovascularisation (CNV), in particular the risk factors for CNV in myopes * To study the subgroup of eyes with macular haemorrhages in the absence of CNV Plan of investigation: 1. Patient with myopia (\>-6.00DS) presents with loss of central vision 2. Examination reveals a macular haemorrhage 3. Investigations * Refraction * Axial length\* * Fundus fluorescein angiography * Indocyanine green angiography\* 4. Determine if a myopic CNV is present or absent 5. Management of patient: Treatment vs No treatment * Treatment being 1. Conventional laser 2. PDT 6. Review at 6 months * BCVA * Clinical appearance (fundal photo) * FFA 7. Review at 12 months * BCVA * Clinical appearance

Interventions

None listed

Sponsors

Singapore National Eye Centre
Lead SponsorOTHER_GOV

Study design

Observational model
DEFINED_POPULATION
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* High myopia (greater than -6.00DS) * Macular haemorrhage

Exclusion criteria

* Macular haemorrhages from other causes eg. diabetic retinopathy, hypertensive retinopathy * Allergy to fluorescein or indocyanine green dyes

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026